What is the primary clinical use of Teflaro (ceftaroline)?

What is the primary clinical use of Teflaro (ceftaroline)?

• A. Community-acquired pneumonia
• B. vancomycin resistant infections
• C. Skin and soft tissue infections
• D. Respiratory infections

Answer: (C)

Teflaro (ceftaroline) is primarily used for the treatment of skin and soft tissue infections, including complicated skin and skin structure infections. Its spectrum of activity includes a variety of gram-positive and some gram-negative bacteria, which is beneficial in treating infections caused by organisms that are resistant to other antibiotics. When it comes to community-acquired pneumonia, while ceftaroline can be used for certain cases, it is not the primary indication. Similarly, it is not specifically indicated for vancomycin-resistant infections despite its activity against some resistant strains. Although ceftaroline does have some efficacy in treating respiratory infections, its primary clinical focus remains on managing skin and soft tissue conditions. Thus, its role in skin and soft tissue infections is what ultimately defines its primary use in clinical practice.

Teflaro (ceftaroline) is primarily used for the treatment of skin and soft tissue infections, including complicated skin and skin structure infections. Its spectrum of activity includes a variety of gram-positive and some gram-negative bacteria, which is beneficial in treating infections caused by organisms that are resistant to other antibiotics.

When it comes to community-acquired pneumonia, while ceftaroline can be used for certain cases, it is not the primary indication. Similarly, it is not specifically indicated for vancomycin-resistant infections despite its activity against some resistant strains. Although ceftaroline does have some efficacy in treating respiratory infections, its primary clinical focus remains on managing skin and soft tissue conditions. Thus, its role in skin and soft tissue infections is what ultimately defines its primary use in clinical practice.